Review

Modeling rare pediatric neurogenetic disorders with IPSCs

  • Intensive research has been performed to identify the pathological mechanisms of many pediatric neurogenetic disorders and to identify potential therapeutic targets. Although research into many pediatric neurological disorders has provided tremendous insight into the mechanisms of disease, effective treatments remain elusive. A significant impediment to progress has been a lack of thorough disease models. Transgenic/knockout animal models have been very valuable in determining the mechanisms of many neurogenetic disorders; however, these models cannot always mimic human-specific pathology and can be inadequate in representing human pathogenesis. This can be especially true for diseases of the nervous system. Alternatively, human patient-derived nervous tissue can be dangerous to acquire and difficult to propagate. The development of patient-derived induced pluripotent stem cells (IPSCs) has given researchers a fresh means of modeling these disorders with renewable human cells that can be used to generate neurons and glia. IPSCs are somatic cells that are reprogrammed back to a pluripotent stage, which can provide an unlimited source of human cells possessing patient-specific genetic mutations. Their potential to be differentiated into any cell type enables them to be a flexible platform to investigate neurogenetic disease. Of course, efficient methods for differentiating IPSCs into homogeneous populations of somatic cells must be established to provide the “disease-in-a-dish” systems. We will discuss the current methods for generating IPSC-derived neural cells to model pediatric neurogenetic disorders, as well as provide examples of the disorders that have been studied that include several neurodevelopmental and neurodegenerative disorders (Rett syndrome, spinal muscular atrophy, hereditary spastic paraplegias, and leukodystrophies). In addition, we provide examples on how patient-specific neural cells can be used in therapeutic development with high-throughput drug screening platforms or with correction via genome editing.

    Citation: Jaemin Kim, David Nonis, Maria Gabriela Otero, Tyler Mark Pierson. Modeling rare pediatric neurogenetic disorders with IPSCs[J]. AIMS Cell and Tissue Engineering, 2019, 3(1): 1-25. doi: 10.3934/celltissue.2019.1.1

    Related Papers:

    [1] Xuecheng Weng, Chang Mei, Farong Gao, Xudong Wu, Qizhong Zhang, Guangyu Liu . A gait stability evaluation method based on wearable acceleration sensors. Mathematical Biosciences and Engineering, 2023, 20(11): 20002-20024. doi: 10.3934/mbe.2023886
    [2] Jinhua Zhou, Shan Jia, Jinbao Chen, Meng Chen . Motion and trajectory planning modeling for mobile landing mechanism systems based on improved genetic algorithm. Mathematical Biosciences and Engineering, 2021, 18(1): 231-252. doi: 10.3934/mbe.2021012
    [3] Teng Li, Xiang Chen, Shuai Cao, Xu Zhang, Xun Chen . Human hands-and-knees crawling movement analysis based on time-varying synergy and synchronous synergy theories. Mathematical Biosciences and Engineering, 2019, 16(4): 2492-2513. doi: 10.3934/mbe.2019125
    [4] Yan Li, Kuan Wang, Lejun Wang, Tongbo Chang, Shengnian Zhang, Wenxin Niu . Biomechanical analysis of the meniscus and cartilage of the knee during a typical Tai Chi movement—brush-knee and twist-step. Mathematical Biosciences and Engineering, 2019, 16(2): 898-908. doi: 10.3934/mbe.2019042
    [5] Sachin Kumar Singh, Dinesh Kumar Vishwakarma, Salwan Ali Abed, Nadhir Al-Ansari, P. S. Kashyap, Akhilesh Kumar, Pankaj Kumar, Rohitashw Kumar, Rajkumar Jat, Anuj Saraswat, Alban Kuriqi, Ahmed Elbeltagi, Salim Heddam, Sungwon Kim . Soil erosion control from trash residues at varying land slopes under simulated rainfall conditions. Mathematical Biosciences and Engineering, 2023, 20(6): 11403-11428. doi: 10.3934/mbe.2023506
    [6] Xiang Wang, Yongcheng Wang, Limin He . An intelligent data analysis-based medical management method for lower limb health of football athletes. Mathematical Biosciences and Engineering, 2023, 20(8): 14005-14022. doi: 10.3934/mbe.2023624
    [7] Lingfei Mo, Lujie Zeng . Running gait pattern recognition based on cross-correlation analysis of single acceleration sensor. Mathematical Biosciences and Engineering, 2019, 16(6): 6242-6256. doi: 10.3934/mbe.2019311
    [8] Satoshi Kumabe, Tianyu Song, Tôn Việt Tạ . Stochastic forest transition model dynamics and parameter estimation via deep learning. Mathematical Biosciences and Engineering, 2025, 22(5): 1243-1262. doi: 10.3934/mbe.2025046
    [9] Xiaoguang Liu, Jiawei Wang, Tie Liang, Cunguang Lou, Hongrui Wang, Xiuling Liu . SE-TCN network for continuous estimation of upper limb joint angles. Mathematical Biosciences and Engineering, 2023, 20(2): 3237-3260. doi: 10.3934/mbe.2023152
    [10] Jiayu Fu, Haiyan Wang, Risu Na, A JISAIHAN, Zhixiong Wang, Yuko OHNO . Recent advancements in digital health management using multi-modal signal monitoring. Mathematical Biosciences and Engineering, 2023, 20(3): 5194-5222. doi: 10.3934/mbe.2023241
  • Intensive research has been performed to identify the pathological mechanisms of many pediatric neurogenetic disorders and to identify potential therapeutic targets. Although research into many pediatric neurological disorders has provided tremendous insight into the mechanisms of disease, effective treatments remain elusive. A significant impediment to progress has been a lack of thorough disease models. Transgenic/knockout animal models have been very valuable in determining the mechanisms of many neurogenetic disorders; however, these models cannot always mimic human-specific pathology and can be inadequate in representing human pathogenesis. This can be especially true for diseases of the nervous system. Alternatively, human patient-derived nervous tissue can be dangerous to acquire and difficult to propagate. The development of patient-derived induced pluripotent stem cells (IPSCs) has given researchers a fresh means of modeling these disorders with renewable human cells that can be used to generate neurons and glia. IPSCs are somatic cells that are reprogrammed back to a pluripotent stage, which can provide an unlimited source of human cells possessing patient-specific genetic mutations. Their potential to be differentiated into any cell type enables them to be a flexible platform to investigate neurogenetic disease. Of course, efficient methods for differentiating IPSCs into homogeneous populations of somatic cells must be established to provide the “disease-in-a-dish” systems. We will discuss the current methods for generating IPSC-derived neural cells to model pediatric neurogenetic disorders, as well as provide examples of the disorders that have been studied that include several neurodevelopmental and neurodegenerative disorders (Rett syndrome, spinal muscular atrophy, hereditary spastic paraplegias, and leukodystrophies). In addition, we provide examples on how patient-specific neural cells can be used in therapeutic development with high-throughput drug screening platforms or with correction via genome editing.


    Every event in gymnastics ends with a landing. In gymnastics competition landing is a crucial factor that affects the final result. However, previous studies indicated a meager rate of landing success in gymnastics, with an error rate as high as 71.9% on floor exercise as shown by 97 men gymnasts in 2004 [1]. Due to aesthetics, the Code of Points of the International Federation of Gymnastics (FIG) does not allow gymnasts to show ground adjustments of their feet, unsteadiness, incomplete twist, loss of balance, and fall [2]. The flexion of the lower limb joints should not be too much to keep an aesthetic and safe posture during dismount. These requirements suggest that gymnasts are trained to use a pattern of stiff landing [3], and their lower limb joints are loaded with higher loadings compared with non-gymnasts [4]. Furthermore, gymnasts are used to loading a tremendous vertical ground reaction force (vGRF) during the landing. The peak vGRF (PvGRF) of forward somersault is 7.6–15.8 body weight (BW), that of backward somersault (BS) is 7.1–13.2 BW [5]. Besides, gymnasts have a high injury risk of the lower limb in dismount [6]. A study has indicated that injuries to the lower limb during competition and practice account for 53% and 69%, respectively, of the total amount of injuries [7].

    Gymnasts should perform every landing as symmetrically as possible. Asymmetrical loading increases lower extremity injury risk [8]. Sabick et al. [9] suggested that gymnasts have more symmetry in vGRF of landing than non-gymnasts, and the excellent symmetry between the legs in gymnasts is likely due to the equally distributed load among the lower limbs to decrease the risk of injury. In contrast to other sports, such as running or ball games, the dismount in gymnastics requires the execution of prescribed movement patterns and a symmetric landing [10]. Therefore, the landing strategy for the entire body and multi-joint movement used by gymnasts may be more complex than that landing in other sports. However, limited studies have used the biomechanical response of lower limbs to analyze the symmetry in the landing of gymnasts.

    Landing is a complex movement under neuromuscular control, involving prediction of the space-time of the touchdown and magnitude of the vGRF. Meanwhile, the angular displacement and position of multi-joints during landing are controlled by the synergy of antagonist-agonist muscles [4]. Leg and joint stiffness of the lower limbs is the most critical regulatory factor during landing. This stiffness is modulated by appropriate muscles pre-activation prior to touchdown during landing [11]. It was reported that the average stiffness of the overall musculoskeletal system is represented by leg stiffness and the mechanics and kinematics of the body's interaction with the ground could also be affected by this stiffness [12]. However, how joint stiffness and the neuromuscular system are modulated during gymnastics landing is unclear. Furthermore, previous studies generally analyzed the whole impact phase that was defined from the initial ground contact to the maximal knee flexion [4] or the maximal descending height of body mass center [13], or the local minima in the vertical reaction force [14], and the first 100 ms [15]. However, there could be different and biomechanical and neuromuscular strategies of the lower limbs during initial and terminal impact-phases of the landing, so we attempt to quantify the kinematics, kinetics, and electromyogram (EMG) characteristics of the lower limbs during the different impact-phases. The results will help elucidate the process of gymnastics landing, energy dissipation, symmetry, and injury mechanism of the lower limbs. Given the ethical limitations, using an in-vivo implanted sensor to test the internal load of the human lower limb is complicated. However, this issue could be solved by computer simulation of movements of human body. Computer simulation of the human body provides a practical approach to explore the characteristics of body motion and has been widely used to analyze body movement in humans [16].

    BS is considered a fundamental skill that competitive gymnasts should a master is used very frequently in gymnastics training and competitions, and is also the basis for developing difficulty levels in movement and combined motion. This study aimed to investigate the biomechanical and neuromuscular strategies of motor control on BS landing. We hypothesized that (1) the flexion of lower limb joints is an active process at initial ground contact, and (2) the gymnast would exhibit different symmetry in kinematics, kinetics, and EMGs recordings between the left and right legs during the landing.

    The participant was an international-level gymnast from the Chinese national team competing in World Cups and Championships (male, mass: 63 kg, age: 17 years), and with no musculoskeletal injuries for at least 6 months prior. A total of 31 individual anthropometric parameters, such as standing height and waist depth, were measured (Table 1). The gymnast read and provided signed informed consent, and the study conformed to the protocol of the Ethical Advisory Committee of China Institute of Sport Science (CISS).

    Table 1.  Anthropometric measurement data (cm).
    Measurements Value Measurements Value Measurements Value
    Standing height 168 Chest breadth 32 Waist circumference 17
    Shoulder height 137 Waist depth 19 Knee height seated 45
    Armpit height 125 Waist breadth 26 Thigh circumference 55
    Waist height 93 Buttock depth 23 Upper leg circumference 41
    Seated height 60 Hip breadth standing 31 Knee circumference 37
    Head length 19 Shoulder to elbow length 32 Calf circumference 38
    Head breadth 16 Forearm–hand length 29 Ankle circumference 23
    Head to chin height 25 Biceps circumference 32 Ankle height, outside 9
    Neck circumference 39 Elbow circumference 29 Foot breadth 9
    Shoulder breadth 38 Forearm circumference 28 Foot length 24
    Chest depth 21

     | Show Table
    DownLoad: CSV

    Kinematic data were collected with a 9-camera Qualisys Oqus motion capture system at 250 Hz. Retro reflective markers (16 mm diameter) were placed at the head, cervical vertebrae (CV7), scapula-inferior angle, thoracic vertebrae (TV10), shoulder, elbow, wrist, anterior superior iliac spine, posterior superior iliac spine, knee, ankle, metatarsal-phalangeal joints, heel, and toes on both sides of the body (Figure 1), the place of these markers were referenced from the CAST full body marker set [17]. A Kistler force plate located beneath a landing mat (5 cm thick), which has little influence on the research since it has been reported that there is less than 5% difference in GRF when the thickness is up to 12 cm thick [14], was used to collect GRF data (1000 Hz), and the surrounding floor was an ethylene-vinyl acetate insole mat. Muscle activation patterns were recorded (surface EMGs, 2000 Hz), with a gain of 3000, from the rectus femoris (RF), biceps femoris (BF), tibialis anterior (TA), and lateral gastrocnemius (LG) on the two lower limbs of the gymnast using a portable DELSYS TrignoTM wireless EMGs system, the place of these EMG sensors were referenced from the SENIAM guidelines [18]. The EMG sensors were fixed on the skin using specialized double-sided tape and medical tape. The Qualisys Oqus motion capture system, the force plate, and the surface EMGs system were all synchronized using a radio signal (Figure 2).

    Figure 1.  Location of retro-reflective markers and EMG sensors on the gymnast. The wireless EMG sensors were positioned on the rectus femoris (RF), biceps femoris (BF), tibialis anterior (TA), and lateral gastrocnemius (LG) of the lower limbs. These sensors were secured with specialized double-sided tape and medical tape. Positions of these markers and sensors were referenced from the CAST full body marker set [17] and the SENIAM guidelines [18], respectively.
    Figure 2.  The diagram of data collection with synchronization. The gymnast performed backward somersault landing after warm-up exercise. Meanwhile, the markers trajectories, ground reaction forces, and EMGs of the gymnast were synchronously recorded using a radio signal. After that, joint forces and moment were calculated using a human multi-body model for analyzing biomechanical and neuromuscular strategies.

    Data collection was conducted in the laboratory of CISS. The gymnast initially performed a warm-up exercise (15 min of jogging, skipping, and stretching). Subsequently, the markers and surface electrodes were placed. The gymnast performed three trials of BS without taking a step or hop. The BS was initiated by jumping from the ground next to the force plate with bare feet, and the best trial was qualitatively judged by two national-level coaches using the Code of Points of the FIG. Meanwhile, the 3D motion data, EMGs, and vGRF data were simultaneously being recorded separately by the Qualisys Oqus motion capture system, the surface EMGs system, and the force plate respectively.

    The GeBod (Generator of Body Data) database (BRG.LifeMODTM) was used to develop a 19-segment rigid-body model based on age, mass, and personalized anthropometric data of the gymnast (Table 1). The measurement parameters used in GeBod are detailed by Cheng et al. [19]. These anthropometrics measures were used to generate a personalized model. The model consisted of the head, neck, upper torso, central torso, lower torso, scapulas, upper arms, lower arms, hands, upper legs, lower legs, feet, and 18 human joints [20], and computer simulation was performed using the landing 3D motion data. A model of gymnastics matting with a dimension of 2 × 2 × 0.05 m (length × width × height) was developed using the MSC.ADAMS (MSC Software Corp. acronym of Automated Dynamic Analysis of Mechanical Systems) software. The base of the mechanical properties of the landing mat was obtained by an optimization algorithm (equations (1) and (2)) [21].

    Δδ=(x1y1)2+(x2y2)2++(xnyn)2n (1)
    S=[ΔT+ΔvGRF+13ΔJo int angles ] (2)

    where xi is the kinematic data from real performance, yi is the kinematic data from computer simulation, and Δδ is RMS (root mean square) error between real performance and simulation; ΔT is expressed as RMS error of time to peak vGRF; ΔνGRF is expressed as RMS error of vertical ground reaction forces; ΔJoint angles is expressed as RMS error of joint angles of lower limbs; and n is the number of data points with each curve; the best optimal parameters are determined when S is the minimum.

    The model was validated by the curve of the dynamic changes (equation (3)) [21].

    CMC=1mi=1nj=1(xijˉxj)2/n(m1)mi=1nj=1(xijˉx)2/(nm1) (3)

    where m is the number of all curves, n is the number of data in each curve, xij is expressed as the j-th data of the i-th curve, ˉxj is the average of the j -th data of all curves, and ˉx is the overall average of data of all curves. To examine the reliability of the model, coefficients of multiple correlation (CMC) between the simulation and actual results from the participant were calculated, with 0.25–0.50, 0.50–0.75, and > 0.75, indicating poor, moderate, and good correlations, respectively [22]. The actual results were recorded during the real performance of the gymnast using the motion capture and force plate, including joint angles of the lower limbs and vGRF.

    Landing impact phase was defined from the touchdown to vGRF equaling to BW, which is after PvGRF. The touchdown was identified as the first frame when vGRF exceeded 10 N [4] on professional software (BioWare, Kistler Instrument Ltd., Switzerland). Meanwhile, the impact phase was divided into two phases (T1: initial impact-phase, from the first touchdown to the PvGRF; T2: terminal impact-phase, from the PvGRF to the vGRF equaling to BW). The joint angles were calculated between two lines in space base on three trajectories, and selected the trajectories that we want to match with the markers. The data for PvGRF was normalized based on the body weight of the gymnast, and impulse of a force was calculated as the integral of the vGRF over its period of application. Power approach was used to determine joint work by quantifying joint velocities (angular) and joint kinetics (torque). Support moment (Ms) is the total extensor pattern at all three joints of the lower limb [23]. Raw EMGs signals were full-wave rectified, and band-pass filtered with a Butterworth filter with cut off frequencies at 10–400 Hz [24]. Pre-activation phase was determined as 100 ms preceding touchdown [25]. The root mean square of EMGs (EMGRMS) was calculated in the pre-activated (T0) and two impact phases of landing (T1 and T2) (equation (4)). The EMGs signals were normalized by peak EMG in the landing phase. In each sub-phase, antagonist–agonist coactivation was calculated as the TA to LG normalized EMGs for the ankle, and the BF to RF normalized EMGs for the knee [26].

    RMS[EMG(t)]=1Tt+TtEMG2(t)dt (4)

    where EMG is the value of the EMG signal at each moment of time (t), and T represents the duration of the analyzed signal.

    The absolute symmetry index (ASI) was used to calculate the symmetry between the feet (equation (5)).

    ASI=|(xlxr)×2(xl+xr)|×100% (5)

    where xl and xr are the values of the landing variable for the left and right foot, respectively. When ASI = 0, the landing is symmetrical. ASI of less than 10% is an acceptable degree of symmetry [27].

    The angles of the two lower limb joints were recorded on the sagittal-plane during the landing. These joint torques were calculated with computer simulation using the software based on the lagrangian formalism [23]. To calculate joint stiffness, the following equation (6) was used:

    Joint stiffness=ΔMΔθ (6)

    where ΔM is the change of the joint torque, and Δθ is the angular displacement of the joint flexion [4].

    The lower limb joints flexed considerably rapidly, and flexions of the hip, knee, and ankle (dorsiflexion) changed by 8°, 20°, and 18°, respectively, on average during T1 (Figure 3). However, the flexion of these joints maintained at around 90º, 120º, and 60º, respectively, during T2 (Figure 3). The ASIs of flexion of these joints were less than 10% (except the ankle during T2, 10.2%). The flexion of the hips, knees, and ankles by simulation correlated well to the actual measured results in the angles of left knee (CMC = 0.95), right knee (CMC = 0.93), and left and right ankles (CMC = 0.85).

    Figure 3.  Joint angles in the sagittal plane during the simulation and actual landing. (a: left leg; b: right leg). The skeleton models showed four body postures of the landing (100 ms prior touchdown, touchdown, peak vertical ground reaction force (vGRF), and vGRF equal to body weight, respectively). (The whole landing process was divided into three phases by dotted lines. T0: The pre-activation phase was defined as 100 ms preceding touchdown; T1: initial impact-phase, from the first touchdown to the peak vGRF; T2: terminal impact-phase, from the peak vGRF to the vGRF equaling to body weight).

    The CMC of the simulated and actual measured vGRF was 0.86, and the measured PvGRF was 12.5 BW. The difference between the measured and simulated PvGRF (11.9 BW) was 4.6%, and the time for the simulated and measured vGRFs to reach a peak differed by 6 ms (Figure 4a). The simulated PvGRFs of the left and right feet were 3614 N and 3610 N, respectively. The impulse of vGRF was shaped like an S curve (Figure 4b), and the impulse increment was the fastest before and after the PvGRF. The joint reaction force (JRF) of the ankles, knees, and hips rapidly increased during T1 (Figure 4c, Figure 4b). In comparison to the PvGRF, peak JRFs of the left ankle, knee, and hip were delayed by 6, 10, and 20 ms, with a delay of 14, 18, and 26 ms for the right side, respectively. The peak JRFs were not reached until T2. Furthermore, hips and knees were loaded by the flexor torque during T1 and by the extensor torque during T2 (Figure 5). The power and work of the hips and knees were considerably altered during T1, and the power and work increment of the joints tended to be relatively stable during T2 (Figure 6). Besides, the increment in the joint stiffness of the hips, knees, and ankles were 2.3, 12.3 and 7.3-fold, respectively, from T1 to T2 (Table 2). Besides, the ASIs of the kinetics (including vGRF, JRF, torque, power, work and stiffness) of the lower limb joints were all more than 10% (Table 3).

    Figure 4.  The measured vertical ground reaction force (vGRF) and the simulated results during the landing (a). Impulse of vGRF (b). Joint reaction force at the lower limbs (c: left leg; d: right leg) during the landing. The skeleton models showed three body postures of the landing (touchdown, peak vGRF, and vGRF equal to body weight, respectively). (The impact phase of landing was divided into two phases by dotted line. T1: initial impact-phase, from the first touchdown to the peak vGRF; T2: terminal impact-phase, from the peak vGRF to the vGRF equaling to body weight).
    Figure 5.  Joint torque at the lower limbs in sagittal plane. Positive values indicate flexor or plantarflexor torque (arrow up), and negative values indicate extensor or dorsiflex torque (arrow down). The support moment (Ms) is the total extensor pattern at all three joints. Ms=Mhip+Mknee+Mankle. The skeleton models showed three body postures of the landing (touchdown, peak vertical ground reaction force (vGRF), and vGRF equal to body weight, respectively). (The impact phase of landing was divided into two phases by dotted line. T1: initial impact-phase, from the first touchdown to the peak vGRF; T2: terminal impact-phase, from the peak vGRF to the vGRF equaling to body weight).
    Figure 6.  Power (a) and work (b) of the lower limbs. Positive and negative values indicate energy generation (concentric muscle action) and energy absorption (eccentric muscle action), respectively. The skeleton models showed three body postures of the landing (touchdown, peak vertical ground reaction force (vGRF), and vGRF equal to body weight, respectively). (The impact phase of landing was divided into two phases by dotted lines. T1: initial impact-phase, from the first touchdown to the peak vGRF; T2: terminal impact-phase, from the peak vGRF to the vGRF equaling to body weight).
    Table 2.  Joint stiffness of the hip, knee, and ankle in the initial impact-phase (T1) and terminal impact-phase (T2). (Nm/kg·deg-1).
    Left hip Left knee Left ankle Right hip Right knee Right ankle
    T1 0.18 0.06 0.01 0.14 0.03 0.02
    T2 0.41 0.46 0.13 0.61 0.58 0.12
    T1: initial impact-phase, from the first touchdown to the peak vertical ground reaction force (vGRF); T2: terminal impact-phase, from the peak vGRF to the vGRF equaling to body weight (BW).

     | Show Table
    DownLoad: CSV
    Table 3.  Absolute symmetry index (ASI) of the lower limbs during the initial impact-phase (T 1) and terminal impact-phase (T 2). (Mean %).
    hip knee ankle foot
    T1 T2 T1 T2 T1 T2 T1 T2
    Kinematics
    Joint angles 2.3 0.6 3.2 1.9 4.5 10.2
    Kinetics
    vertical GRF 21.1 42.5
    Joint reaction force 17.7 59.4 26.0 52.8 33.3 48.5
    Joint torque 70.4 82.5 42.0 51.7 39.1 27.2
    Power 99.0 148.3 50.7 259.3 129.3 201.3
    Work 101.8 109.6 62.5 54.1 33.3 47.4
    Joint stiffness 23.0 39.7 60.1 23.8 49.8 12.4
    Electromyography
    Coactivation 157.5 11.0 32.7 57.4
    T1: initial impact-phase, from the first touchdown to the peak vertical ground reaction force (vGRF); T2: terminal impact-phase, from the peak vGRF to the vGRF equaling to body weight (BW).

     | Show Table
    DownLoad: CSV

    The EMGs of all examined muscles (RF, BF, TA, and LG of the both lower limbs) were activated during T0, and the peak EMGs were all in T2 (Figure 7a), except that of the TA of the left leg. Furthermore, the EMGRMS approximately showed an elevating trend from T0 to T2 and increased dramatically during T2 (average 4.8-fold larger than that during T1) (Figure 7b). More specifically, the coactivation of the knees and ankles all ranged between 0.76 and 1.38 during T2, which involved the highest activation level, and their ASIs were more than 10% during T1 and T2 (Table 3).

    Figure 7.  Coactivation of normalized EMGs (a) and root mean square of normalized EMG (EMGRMS) (b). Positive EMG/EMGRMS means antagonist of the joint, and negative EMG/EMGRMS means the agonist of the joint. The EMGs were normalized to the peak EMG during the landing phase. The coactivation was defined as the TA to LG EMGs for the ankle, and the BF to RF EMGs for the knee. (RF: rectus femoris, BF: biceps femoris, TA: tibialis anterior, LG: lateral gastrocnemius). The skeleton models showed four body postures of the landing (100 ms prior touchdown, touchdown, peak vertical ground reaction force (vGRF), and vGRF equal to body weight, respectively). (The whole landing process was separated into three phases by dotted lines. T0: The pre-activation phase was defined as 100 ms preceding touchdown; T1: initial impact-phase, from the first touchdown to the peak vGRF; T2: terminal impact-phase, from the peak vGRF to the vGRF equaling to body weight).

    This work is the first to comprehensively investigate the biomechanical and neuromuscular strategies during BS landing performed by an international level gymnast during initial (T1) and terminal (T2) impact-phase. The lower limb joints showed flexor torque in T1 and extensor torque in T2; during T2, the JRFs, joint torques, joint stiffness, and EMGs were higher than those in T1, but the flexions of the lower limb joints in T2 were less. Furthermore, these flexions showed symmetry between the left and right legs during the landing, but the kinetics and EMGs data were asymmetrical.

    The model successfully reproduced the joint angles and kinetics characteristic of the BS landing. The measured flexion of the lower limb joints and vGRF were close to the simulation results. The CMCs presented high correlation (>0.75). Furthermore, the difference between the simulated (11.9 BW) and measured PvGRF (12.5 BW) was 4.6%. The PvGRF was consistent with that of previous studies (7.1–13.2 BW) [5]. Therefore, the results suggested the human model was valid.

    Neuromuscular pre-activation plays a significant role in the landing strategy. The RF, BF, LG, and TA of the lower limbs were activated during T0. Previous studies also showed that the LG, TA, and vastus lateralis of gymnasts were all in the pre-activated phase before touchdown and that the activation level of gymnasts was higher than that of non-gymnasts [4].

    As hypothesized, the landing strategy of the gymnast was to actively flex his lower limb joints in the initial impact-phase (T1). Flexion and flexor torques of the hips, knees, and ankles rapidly increased during T1. The lower limb joints were suggested to actively flex to absorb considerable kinetic energy. An appropriate lower limb joint angle during the dismount of touchdown raises the ability of the muscles to absorb energy [28]. In this study, the time to PvGRF was 30 ms, which was close to that in our previous results [21]. The energy during landing can be absorbed by athletes through flexion motion of the lower limb joints [15]. More impact energy could also be dissipated with greater flexion angle of the lower limb joints [3,5]. However, the flexion angle of these joints should be minimized during landing because of the restriction of gymnastic regulations [2]. Thus, energy dissipation was probably limited during T1 for the gymnast.

    The landing strategy of the gymnast was to dissipate the landing impact, controlling the flexion movements of the lower limbs in a small range during the terminal impact-phase (T2). The angle of the lower limb joints changed by a lesser amount, indicating that the body tended to stabilize. T2 took a relatively long time (approximately five times of T1), but increment in the impulses of the lower limb was less than one-third of that in T1, thus the landing impact was well dissipated. Furthermore, the JRF of the ankles, knees, and hips rapidly increased during T1, but their peaks were reached during T2. This result indicates the delay effect of the JRF by 14-26 ms after PvGRF and that the conduction of vGRF to the human body was a gradual process from the ankle to the knee and then to the hip. Therefore, the force was successively reduced, and dissipating of the landing impact was realized by the excellent coordination of the three lower limb joints to adequately protect the trunk and cephalic organs [29]. Moreover, the support moment is the total extensor pattern at all three joints, and therefore it contributes to defending against the landing-induced body collapse [23]. The eccentric work of the knee joint was maximum, followed by the hip and ankle joints, which was consistent with the overall trend of the results during the drop landing in previous studies [6]. On the other hand, the stiffness and EMGRMS of both the lower limb joints increased several times from T1 to T2. Therefore, the co-contraction could increase joint stiffness, thereby limiting the flexion of the lower limb joints to achieve more stable gymnastic landing performance. Park and Durand [30] suggested that joint stiffness is nearly controlled by the level of muscle co-contraction. The ankle needed to bear the maximum impact load, but lack of effective energy dissipation due to minimum flexion angle and eccentric work. Therefore, we speculated that the risk of injury of the ankle was probably the highest during gymnastic landing among the lower limb joints, which was consistent with the findings of an epidemiological investigation [29].

    The gymnast exhibited a different symmetry in kinematics, kinetics, and EMGs between the left and right legs during the landing. During the entire impact phase of the landing (T1 and T2), the difference between flexions of both hip and knee joints was within 5°, and the difference in ankle dorsiflexion was within 10°. Furthermore, the ASIs of flexion of the lower limb joints were less than 10%. These results showed an excellent landing symmetry in sports performance. However, the ASIs of the kinetics (including vGRF, JRF, torque, power, work and stiffness) and EMGs (coactivation) of the lower limb joints were all more than 10%. The ASI of the power of ankle was even more than 200% in T2. Sabick et al. [9] speculated that a good landing symmetry between the legs in gymnasts is likely due to the equal distribution of load among the lower limbs. However, similar results were not noted in this study. This could be an indication that the internal load of the lower limb joints can efficiently modulate the landing symmetry. Van Emmerik et al. [31] suggested that the human dynamic system plays a regulatory role in the completion of movement. The change in multiple joint forces can affect the athletes' kinematic performance during sprints [32]. Therefore, a symmetrical landing could be better performed by modulating the kinetics and EMGs of the lower limbs, including vGRF, JRF, torque, stiffness, power, and eccentric work of multi-joints, and synergy of antagonist and agonist muscles.

    This study had two main limitations. First, the computer simulation model was a multi-rigid body without considering the shock of soft tissues. Second, only one participant was included in the study, but the landing was comprehensively analyzed using kinematic, kinetic, and EMGs data from the international-level gymnast during initial and terminal impact-phases, these characteristics that is one of the representatives of excellent gymnastic landings. Nonetheless, most results of the model were in line with those obtained in experimental studies. Detailed musculoskeletal models may enhance our understanding of the loadings of the lower limb joints, particularly related to soft tissues. Future studies might focus on how more gymnasts manage their landing motion to ensure symmetry.

    An international-level gymnast employs complex biomechanical and neuromuscular landing strategies to perform BS successfully. The relevant lower limb muscles initially pre-activate before touchdown to adequately prepare for landing. Subsequently, the gymnast actively flexes the lower limb joints at initial ground contact and then struggles to extend the joints to dissipate the landing impact and maintain an unchanged posture. Meanwhile, the gymnast may modulate lower limb joints loading and muscle activation of both the lower limbs to achieve landing symmetry. The findings of this study may expand our knowledge about gymnastics landing.

    This study was supported by the National Key R & D Program of China (No. 2017YFC0803802), the National Natural Science Foundation of China (No. 11672080, 31700815), and the Chongqing Natural Science Foundation of China under Grant (No. cstc2018jcyjAX0086). The authors are thankful to the Chinese national gymnastics team for their valuable collaboration.

    This manuscript has not been published or presented elsewhere in part or in entirety and is not under consideration by another journal. All authors have read and approve the content of the manuscript. The study participant provided informed consent, and the study design was approved by the appropriate ethics review board. We have read and understood your journal's policies, and we believe that neither the manuscript nor the study violates any of these. There are no conflicts of interest to declare.



    [1] Bürk K (2017) Friedreich Ataxia: current status and future prospects. Cerebellum Ataxias.
    [2] Leonard H, Cobb S, Downs J (2016) Clinical and biological progress over 50 years in Rett syndrome. Nat Rev Neurol 13: 37–51.
    [3] Auburger G, Klinkenberg M, Drost J, et al. (2012) Primary Skin Fibroblasts as a Model of Parkinson's Disease. Mol Neurobiol 46: 20–27. doi: 10.1007/s12035-012-8245-1
    [4] Petters RM, Sommer JR (2000) Transgenic animals as models for human disease. Transgenic Res 9: 347–351. doi: 10.1023/A:1008926303533
    [5] Hargus G, Ehrlich M, Hallmann AL, et al. (2014) Human stem cell models of neurodegeneration: A novel approach to study mechanisms of disease development. Acta Neuropathol 127: 151–173. doi: 10.1007/s00401-013-1222-6
    [6] Ilic D, Ogilvie C (2017) Concise Review: Human Embryonic Stem Cells-What Have We Done? What Are We Doing? Where Are We Going? Stem Cells 35: 17–25.
    [7] Randolph LN, Jiang Y, Lian X (2017) Stem Cell Engineering and Differentiation for Disease Modeling and Cell-based Therapies. AIMS Cell Tissue Eng 1: 140–157. doi: 10.3934/celltissue.2017.2.140
    [8] Takahashi K, Yamanaka S (2006) Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors. Cell 126: 663–676. doi: 10.1016/j.cell.2006.07.024
    [9] Takahashi K, Tanabe K, Ohnuki M, et al. (2007) Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors. Cell 131: 861–872. doi: 10.1016/j.cell.2007.11.019
    [10] Poon A, Zhang Y, Chandrasekaran A, et al. (2017) Modeling neurodegenerative diseases with patient-derived induced pluripotent cells: Possibilities and challenges. N Biotechnol 39: 190–198. doi: 10.1016/j.nbt.2017.05.009
    [11] Tabar V, Studer L (2014) Pluripotent stem cells in regenerative medicine: Challenges and recent progress. Na Rev Genet 15: 82–92. doi: 10.1038/nrg3563
    [12] Mertens J, Marchetto MC, Bardy C, et al. (2016) Evaluating cell reprogramming, differentiation and conversion technologies in neuroscience. Nat Rev Neurosci 17: 424–437. doi: 10.1038/nrn.2016.46
    [13] Lancaster M, Renner M, Martin C, et al. (2013) Cerebral organoids model human brain development and microcephaly. Nature 501: 373–379. doi: 10.1038/nature12517
    [14] Pasca AM, Sloan SA, Clarke LE, et al. (2015) Functional cortical neurons and astrocytes from human pluripotent stem cells in 3D culture. Nat Methods 12: 671–678. doi: 10.1038/nmeth.3415
    [15] Soldner F, Laganière J, Cheng AW, et al. (2011) Generation of Isogenic Pluripotent Stem Cells Differing Exclusively at Two Early Onset Parkinson Point Mutations. Cell 146: 318–331. doi: 10.1016/j.cell.2011.06.019
    [16] Bassett AR (2017) Editing the genome of hiPSC with CRISPR/Cas9: disease models. Mamm Genome 28: 348–364. doi: 10.1007/s00335-017-9684-9
    [17] Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. (1998) Embryonic stem cell lines derived from human blastocysts. Science 282: 1145–1147.
    [18] Wilmut I, Schnieke AE, McWhir J, et al. (1997) Viable offspring derived from fetal and adult mammalian cells. Nature 385: 810–813. doi: 10.1038/385810a0
    [19] Cowan CA, Atienza J, Melton DA, et al. (2005) Nuclear reprogramming of somatic cells after fusion with human embryonic stem cells. Science 309: 1369–1373. doi: 10.1126/science.1116447
    [20] Yu J, Vodyanik MA, Smuga-Otto K, et al. (2007) Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells. Science 318: 1917–1920. doi: 10.1126/science.1151526
    [21] Okita K, Matsumura Y, Sato Y, et al. (2011) A more efficient method to generate integration-free human iPS cells. Nat Methods 8: 409. doi: 10.1038/nmeth.1591
    [22] Daley GQ (2014) Dissecting reprogramming, differentiation and conversion with network biology. Leuk Suppl 3: S3–S4. doi: 10.1038/leusup.2014.2
    [23] Zhou W, Freed CR (2009) Adenoviral Gene Delivery Can Reprogram Human Fibroblasts to Induced Pluripotent Stem Cells. Stem Cells 27: 2667–2674. doi: 10.1002/stem.201
    [24] Zhou Y, Zeng F (2013) Integration-free Methods for Generating Induced Pluripotent Stem Cells. Genom Proteom Bioinform 11: 284–287. doi: 10.1016/j.gpb.2013.09.008
    [25] Nakanishi M, Otsu M (2012) Development of Sendai Virus Vectors and their Potential Applications in Gene Therapy and Regenerative Medicine. Curr Gene Ther 12: 410–416. doi: 10.2174/156652312802762518
    [26] Kim D, Kim CH, Moon JI, et al. (2009) Generation of Human Induced Pluripotent Stem Cells by Direct Delivery of Reprogramming Proteins. Cell Stem Cell 4: 472–476. doi: 10.1016/j.stem.2009.05.005
    [27] Okita K, Yamanaka S (2011) Induced pluripotent stem cells: opportunities and challenges. Philos Trans R Soc B Biol Sci 366: 2198–2207. doi: 10.1098/rstb.2011.0016
    [28] Paridaen JT, Huttner WB (2014) Neurogenesis during development of the vertebrate central nervous system. EMBO Rep 15: 351–364. doi: 10.1002/embr.201438447
    [29] Chandrasekaran A, Avci HX, Ochalek A, et al. (2017) Comparison of 2D and 3D neural induction methods for the generation of neural progenitor cells from human induced pluripotent stem cells. Stem Cell Res 25: 139–151. doi: 10.1016/j.scr.2017.10.010
    [30] Chuang JH (2015) Neural differentiation from embryonic stem cells in vitro : An overview of the signaling pathways. World J Stem Cells 7: 437. doi: 10.4252/wjsc.v7.i2.437
    [31] Chambers SM, Fasano CA, Papapetrou EP, et al. (2009) Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol 27: 275–280. doi: 10.1038/nbt.1529
    [32] Qi Y, Zhang XJ, Renier N, et al. (2017) Combined small-molecule inhibition accelerates the derivation of functional cortical neurons from human pluripotent stem cells. Nat Biotechnol 35: 154–163. doi: 10.1038/nbt.3777
    [33] Kim DS, Jung SJ, Lee JS, et al. (2017) Rapid generation of OPC-like cells from human pluripotent stem cells for treating spinal cord injury. Exp Mole Med 49: e361. doi: 10.1038/emm.2017.106
    [34] Wang S, Bates J, Li X, et al. (2013) Human iPSC-derived oligodendrocyte progenitor cells can myelinate and rescue a mouse model of congenital hypomyelination. Cell Stem Cell 12: 252–264. doi: 10.1016/j.stem.2012.12.002
    [35] Xu XH, Zhong Z (2013) Disease modeling and drug screening for neurological diseases using human induced pluripotent stem cells. Acta Pharmacol Sin 34: 755–764. doi: 10.1038/aps.2013.63
    [36] Lojewski X, Staropoli JF, Biswas-legrand S, et al. (2014) Human iPSC models of neuronal ceroid lipofuscinosis capture distinct effects of TPP1 and CLN3 mutations on the endocytic pathway. Hum Mol Genet 23: 2005–2022. doi: 10.1093/hmg/ddt596
    [37] Espuny-Camacho I, Michelsen KA, Linaro D, et al. (2018) Human Pluripotent Stem-Cell-Derived Cortical Neurons Integrate Functionally into the Lesioned Adult Murine Visual Cortex in an Area-Specific Way. Cell Rep 23: 2732–2743. doi: 10.1016/j.celrep.2018.04.094
    [38] Dwyer ND, Chen B, Chou SJ, et al. (2016) Neural Stem Cells to Cerebral Cortex: Emerging Mechanisms Regulating Progenitor Behavior and Productivity. J Neurosci 36: 11394–11401. doi: 10.1523/JNEUROSCI.2359-16.2016
    [39] Rigamonti A, Repetti GG, Sun C, et al. (2016) Large-Scale Production of Mature Neurons from Human Pluripotent Stem Cells in a Three-Dimensional Suspension Culture System. Stem cell Rep 6: 993–1008. doi: 10.1016/j.stemcr.2016.05.010
    [40] Gunhanlar N, Shpak G, van der Kroeg M, et al. (2018) A simplified protocol for differentiation of electrophysiologically mature neuronal networks from human induced pluripotent stem cells. Mol Psychiatry 23: 1336–1344. doi: 10.1038/mp.2017.56
    [41] Alcamo EA, Chirivella L, Dautzenberg M, et al. (2008) Satb2 regulates callosal projection neuron identity in the developing cerebral cortex. Neuron 57: 364–377. doi: 10.1016/j.neuron.2007.12.012
    [42] Britanova O, de Juan Romero C, Cheung A, et al. (2008) Satb2 is a postmitotic determinant for upper-layer neuron specification in the neocortex. Neuron 57: 378–392. doi: 10.1016/j.neuron.2007.12.028
    [43] Shi Y, Kirwan P, Livesey FJ (2012) Directed differentiation of human pluripotent stem cells to cerebral cortex neurons and neural networks. Nat Protoc 7: 1836–1846. doi: 10.1038/nprot.2012.116
    [44] Chen B, Wang SS, Hattox AM, et al. (2008) The Fezf2-Ctip2 genetic pathway regulates the fate choice of subcortical projection neurons in the developing cerebral cortex. Proc Nat Acad Sci 105: 11382–11387. doi: 10.1073/pnas.0804918105
    [45] Espuny-Camacho I, Michelsen KA, Gall D, et al. (2013) Pyramidal neurons derived from human pluripotent stem cells integrate efficiently into mouse brain circuits in vivo. Neuron 77: 440–456. doi: 10.1016/j.neuron.2012.12.011
    [46] Elkabetz Y, Panagiotakos G, Al Shamy G, et al. (2008) Human ES cell-derived neural rosettes reveal a functionally distinct early neural stem cell stage. Genes Dev 22: 152–165. doi: 10.1101/gad.1616208
    [47] Paşca SP, Portmann T, Voineagu I, et al. (2011) Using iPSC-derived neurons to uncover cellular phenotypes associated with Timothy syndrome. Nat Med 17: 1657–1662. doi: 10.1038/nm.2576
    [48] Davis-Dusenbery BN, Williams LA, Klim JR, et al. (2014) How to make spinal motor neurons. Development 141: 491–501. doi: 10.1242/dev.097410
    [49] Santiago C, Bashaw GJ (2014) Transcription factors and effectors that regulate neuronal morphology. Development 141: 4667–4680. doi: 10.1242/dev.110817
    [50] Stifani N (2014) Motor neurons and the generation of spinal motor neuron diversity. Front Cell Neurosci 8: 293.
    [51] Du ZW, Chen H, Liu H, et al. (2015) Generation and expansion of highly pure motor neuron progenitors from human pluripotent stem cells. Nat Commun 6: 6626. doi: 10.1038/ncomms7626
    [52] Hester ME, Murtha MJ, Song S, et al. (2011) Rapid and efficient generation of functional motor neurons from human pluripotent stem cells using gene delivered transcription factor codes. Mol Ther 19: 1905–1912. doi: 10.1038/mt.2011.135
    [53] Di Giorgio FP, Boulting GL, Bobrowicz S, et al. (2008) Human Embryonic Stem Cell-Derived Motor Neurons Are Sensitive to the Toxic Effect of Glial Cells Carrying an ALS-Causing Mutation. Cell Stem Cell 3: 637–648. doi: 10.1016/j.stem.2008.09.017
    [54] Amoroso MW, Croft GF, Williams DJ, et al. (2013) Accelerated high-yield generation of limb-innervating motor neurons from human stem cells. J Neurosci 33: 574–586. doi: 10.1523/JNEUROSCI.0906-12.2013
    [55] Karumbayaram S, Novitch BG, Patterson M, et al. (2009) Directed differentiation of human-induced pluripotent stem cells generates active motor neurons. Stem Cells 27: 806–811. doi: 10.1002/stem.31
    [56] Toma JS, Shettar BC, Chipman PH, et al. (2015) Motoneurons derived from induced pluripotent stem cells develop mature phenotypes typical of endogenous spinal motoneurons. J Neurosci 35: 1291–1306. doi: 10.1523/JNEUROSCI.2126-14.2015
    [57] Pepper JP, Wang TV, Hennes V, et al. (2017) Human induced pluripotent stem cell–derived motor neuron transplant for neuromuscular atrophy in a mouse model of sciatic nerve injury. JAMA Facial Plast Surg 19: 197. doi: 10.1001/jamafacial.2016.1544
    [58] Chandrasekaran A, Avci HX, Leist M, et al. (2016) Astrocyte differentiation of human pluripotent stem cells: New tools for neurological disorder research. Front Cell Neurosci 10: 215.
    [59] Santos R, Vadodaria KC, Jaeger BN, et al. (2017) Differentiation of inflammation-responsive astrocytes from glial progenitors generated from human induced pluripotent stem cells. Stem Cell Rep 8: 1757–1769. doi: 10.1016/j.stemcr.2017.05.011
    [60] TCW J, Wang M, Pimenova AA, et al. (2017) An Efficient Platform for Astrocyte Differentiation from Human Induced Pluripotent Stem Cells. Stem Cell Rep 9: 600–614. doi: 10.1016/j.stemcr.2017.06.018
    [61] Liu H, Zhang SC (2011) Specification of neuronal and glial subtypes from human pluripotent stem cells. Cell Mol Life Sci 68: 3995–4008. doi: 10.1007/s00018-011-0770-y
    [62] Krencik R, Weick JP, Liu Y, et al. (2011) Specification of transplantable astroglial subtypes from human pluripotent stem cells. Nat Biotechnol 29: 528–534. doi: 10.1038/nbt.1877
    [63] Jiang P, Chen C, Liu XB, et al. (2016) Human iPSC-Derived Immature Astroglia Promote Oligodendrogenesis by Increasing TIMP-1 Secretion. Cell Rep 15: 1303–1315. doi: 10.1016/j.celrep.2016.04.011
    [64] Nistor GI, Totoiu MO, Haque N, et al. (2005) Human embryonic stem cells differentiate into oligodendrocytes in high purity and myelinate after spinal cord transplantation. Glia 49: 385–396. doi: 10.1002/glia.20127
    [65] Hu BY, Du ZW, Zhang SC (2009) Differentiation of human oligodendrocytes from pluripotent stem cells. Nat Protoc 4: 1614–1622. doi: 10.1038/nprot.2009.186
    [66] Goldman SA, Kuypers NJ (2015) How to make an oligodendrocyte. Development 142: 3983–3995. doi: 10.1242/dev.126409
    [67] Doerr J, Böckenhoff A, Ewald B, et al. (2015) Arylsulfatase A Overexpressing Human iPSC-derived Neural Cells Reduce CNS Sulfatide Storage in a Mouse Model of Metachromatic Leukodystrophy. Mol Ther 23: 1519–1531. doi: 10.1038/mt.2015.106
    [68] Pouya A, Satarian L, Kiani S, et al. (2011) Human induced pluripotent stem cells differentiation into oligodendrocyte progenitors and transplantation in a rat model of optic chiasm demyelination. PLoS One 6: e27925. doi: 10.1371/journal.pone.0027925
    [69] Lippmann ES, Azarin SM, Kay JE, et al. (2012) Derivation of blood-brain barrier endothelial cells from human pluripotent stem cells. Na Biotechnol 30: 783–791. doi: 10.1038/nbt.2247
    [70] Appelt-Menzel A, Cubukova A, Günther K, et al. (2017) Establishment of a human blood-brain barrier co-culture model mimicking the neurovascular unit using induced pluri- and multipotent stem cells. Stem Cell Rep 8: 894–906. doi: 10.1016/j.stemcr.2017.02.021
    [71] Busskamp V, Lewis NE, Guye P, et al. (2014) Rapid neurogenesis through transcriptional activation in human stem cells. Mol Syst Biol 10: 760–760. doi: 10.15252/msb.20145508
    [72] Zhang Y, Pak CH, Han Y, et al. (2013) Rapid single-step induction of functional neurons from human pluripotent stem cells. Neuron 78: 785–798. doi: 10.1016/j.neuron.2013.05.029
    [73] Wang C, Ward ME, Chen R, et al. (2017) Scalable Production of iPSC-Derived Human Neurons to Identify Tau-Lowering Compounds by High-Content Screening. Stem Cell Rep 9: 1221–1233. doi: 10.1016/j.stemcr.2017.08.019
    [74] Fernandopulle MS, Prestil R, Grunseich C, et al. (2018) Transcription Factor–Mediated Differentiation of Human iPSCs into Neurons. Curr Protoc Cell Biol 79: e51. doi: 10.1002/cpcb.51
    [75] Li X, Tao Y, Bradley R, et al. (2018) Fast Generation of Functional Subtype Astrocytes from Human Pluripotent Stem Cells. Stem Cell Rep 11: 998–1008. doi: 10.1016/j.stemcr.2018.08.019
    [76] Ehrlich M, Mozafari S, Glatza M, et al. (2017) Rapid and efficient generation of oligodendrocytes from human induced pluripotent stem cells using transcription factors. Proc Natl Acade Sci U S A 114: E2243–E2252. doi: 10.1073/pnas.1614412114
    [77] García-León JA, Kumar M, Boon R, et al. (2018) SOX10 Single Transcription Factor-Based Fast and Efficient Generation of Oligodendrocytes from Human Pluripotent Stem Cells. Stem Cell Rep 10: 655–672. doi: 10.1016/j.stemcr.2017.12.014
    [78] Ardhanareeswaran K, Mariani J, Coppola G, et al. (2017) Human induced pluripotent stem cells for modelling neurodevelopmental disorders. Nat Rev Neurol 13: 265–278. doi: 10.1038/nrneurol.2017.45
    [79] Shovlin S, Tropea D (2018) Transcriptome level analysis in Rett syndrome using human samples from different tissues. Orphanet J Rare Dis 13: 113. doi: 10.1186/s13023-018-0857-8
    [80] Chahrour M, Zoghbi HY (2007) The Story of Rett Syndrome: From Clinic to Neurobiology. Neuron 56: 422–437. doi: 10.1016/j.neuron.2007.10.001
    [81] Huidobro C, Fernandez AF, Fraga MF (2013) The role of genetics in the establishment and maintenance of the epigenome. Cell Mol Life Sci 70: 1543–1573. doi: 10.1007/s00018-013-1296-2
    [82] Kishi N, Macklis JD (2004) MECP2 is progressively expressed in post-migratory neurons and is involved in neuronal maturation rather than cell fate decisions. Mol Cell Neurosci 27: 306–321. doi: 10.1016/j.mcn.2004.07.006
    [83] Damen D, Heumann R (2013) MeCP2 phosphorylation in the brain: From transcription to behavior. Biol Chem 394: 1595–1605.
    [84] Hendrich B, Bird A (1998) Identification and Characterization of a Family of Mammalian Methyl-CpG Binding Proteins. Mol Cell Biol 18: 6538–6547. doi: 10.1128/MCB.18.11.6538
    [85] Gold WA, Krishnarajy R, Ellaway C, et al. (2018) Rett Syndrome: A Genetic Update and Clinical Review Focusing on Comorbidities. ACS Chem Neurosci 9: 167–176. doi: 10.1021/acschemneuro.7b00346
    [86] Ausió J (2018) Role of MeCP2 in neurological disorders: current status and future perspectives. Epigenomics 10: 5–8. doi: 10.2217/epi-2017-0128
    [87] Linda K, Fiuza C, Nadif Kasri N (2018) The promise of induced pluripotent stem cells for neurodevelopmental disorders. Prog Neuropsychopharmacol Biol Psychiatry 84: 382–391. doi: 10.1016/j.pnpbp.2017.11.009
    [88] Marchetto MC, Carromeu C, Acab A, et al. (2010) A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell 143: 527–539. doi: 10.1016/j.cell.2010.10.016
    [89] Kim KY, Hysolli E, Park IH (2011) Neuronal maturation defect in induced pluripotent stem cells from patients with Rett syndrome. Proc Natl Acad Sci U S A 108: 14169–14174. doi: 10.1073/pnas.1018979108
    [90] Farra N, Zhang WB, Pasceri P, et al. (2012) Rett syndrome induced pluripotent stem cell-derived neurons reveal novel neurophysiological alterations. Mol Psychiatry 17: 1261–1271. doi: 10.1038/mp.2011.180
    [91] Cheung AY, Horvath LM, Grafodatskaya D, et al. (2011) Isolation of MECP2-null Rett Syndrome patient hiPS cells and isogenic controls through X-chromosome inactivation. Hum Mol Genet 20: 2103–2115. doi: 10.1093/hmg/ddr093
    [92] Djuric U, Cheung AYL, Zhang W, et al. (2015) MECP2e1 isoform mutation affects the form and function of neurons derived from Rett syndrome patient iPS cells. Neurobiol Dis 76: 37–45. doi: 10.1016/j.nbd.2015.01.001
    [93] Lioy DT, Garg SK, Monaghan CE, et al. (2011) A role for glia in the progression of Rett's syndrome. Nature 475: 497–500. doi: 10.1038/nature10214
    [94] Williams EC, Zhong X, Mohamed A, et al. (2014) Mutant astrocytes differentiated from Rett syndrome patients-specific iPSCs have adverse effects on wildtype neurons. Hum Mol Genet 23: 2968–2980. doi: 10.1093/hmg/ddu008
    [95] Pearn JH (1978) Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy. J Med Genet 15: 409–413. doi: 10.1136/jmg.15.6.409
    [96] Ebert AD, Svendsen CN (2010) Stem cell model of spinal muscular atrophy. Arch Neurol 67: 665–669.
    [97] Sareen D, Ebert AD, Heins BM, et al. (2012) Inhibition of apoptosis blocks human motor neuron cell death in a stem cell model of spinal muscular atrophy. PLoS One 7: e39113. doi: 10.1371/journal.pone.0039113
    [98] Liu Q, Fischer U, Wang F, et al. (1997) The spinal muscular atrophy disease gene product, SMN, and its associated protein SIP1 are in a complex with spliceosomal snRNP proteins. Cell 90: 1013–1021. doi: 10.1016/S0092-8674(00)80367-0
    [99] Fischer U, Liu Q, Dreyfuss G (1997) The SMN-SIP1 complex has an essential role in spliceosomal snRNP biogenesis. Cell 90: 1023–1029. doi: 10.1016/S0092-8674(00)80368-2
    [100] Rossoll W, Jablonka S, Andreassi C, et al. (2003) Smn, the spinal muscular atrophy-determining gene product, modulates axon growth and localization of β-actin mRNA in growth cones of motoneurons. J Cell Biol 163: 801–812. doi: 10.1083/jcb.200304128
    [101] Farrar MA, Kiernan MC (2015) The Genetics of Spinal Muscular Atrophy: Progress and Challenges. Neurotherapeutics 12: 290–302. doi: 10.1007/s13311-014-0314-x
    [102] Corti S, Nizzardo M, Simone C, et al. (2012) Genetic correction of human induced pluripotent stem cells from patients with spinal muscular atrophy. Sci Transl Med 4: 165ra162.
    [103] Yoshida M, Kitaoka S, Egawa N, et al. (2015) Modeling the early phenotype at the neuromuscular junction of spinal muscular atrophy using patient-derived iPSCs. Stem Cell Rep 4: 561–568. doi: 10.1016/j.stemcr.2015.02.010
    [104] Mcgivern JV, Patitucci TN, Nord JA, et al. (2013) Spinal muscular atrophy astrocytes exhibit abnormal calcium regulation and reduced growth factor production. Glia 61: 1418–1428. doi: 10.1002/glia.22522
    [105] Zhou C, Feng Z, Ko CP (2016) Defects in Motoneuron-Astrocyte Interactions in Spinal Muscular Atrophy. J Neurosci 36: 2543–2553. doi: 10.1523/JNEUROSCI.3534-15.2016
    [106] Almad AA, Maragakis NJ (2012) Glia: An emerging target for neurological disease therapy. Stem Cell Res Ther 3: 37. doi: 10.1186/scrt128
    [107] Cloake NC, Yan J, Aminian A, et al. (2018) PLP1 mutations in patients with multiple sclerosis: Identification of a new mutation and potential pathogenicity of the mutations. J Clin Med 7: 100. doi: 10.3390/jcm7050100
    [108] Hobson GM, Kamholz J (1993) PLP1-Related Disorders. GeneReviews®.
    [109] Garbern JY (2007) Pelizaeus-Merzbacher disease: Genetic and cellular pathogenesis. Cell Mol Life Sci 64: 50–65. doi: 10.1007/s00018-006-6182-8
    [110] Numasawa-Kuroiwa Y, Okada Y, Shibata S, et al. (2014) Involvement of ER stress in dysmyelination of pelizaeus-merzbacher disease with PLP1 missense mutations shown by iPSC-derived oligodendrocytes. Stem Cell Rep 2: 648–661. doi: 10.1016/j.stemcr.2014.03.007
    [111] Takahashi T, Suzuki T (2012) Role of sulfatide in normal and pathological cells and tissues. J Lipid Res 53: 1437–1450. doi: 10.1194/jlr.R026682
    [112] Patil SA, Maegawa GHB (2013) Developing therapeutic approaches for metachromatic leukodystrophy. Drug Des Devel Ther 7: 729–745.
    [113] Ramakrishnan H, Hedayati KK, Lüllmann-Rauch R, et al. (2007) Increasing sulfatide synthesis in myelin-forming cells of arylsulfatase A-deficient mice causes demyelination and neurological symptoms reminiscent of human metachromatic leukodystrophy. J Neurosci 27: 9482–9490. doi: 10.1523/JNEUROSCI.2287-07.2007
    [114] Deconinck N, Messaaoui A, Ziereisen F, et al. (2008) Metachromatic leukodystrophy without arylsulfatase A deficiency: A new case of saposin-B deficiency. Eur J Paediatr Neurol 12: 46–50. doi: 10.1016/j.ejpn.2007.05.004
    [115] Frati G, Luciani M, Meneghini V, et al. (2018) Human iPSC-based models highlight defective glial and neuronal differentiation from neural progenitor cells in metachromatic leukodystrophy. Cell Death Dis 9: 698. doi: 10.1038/s41419-018-0737-0
    [116] Meneghini V, Frati G, Sala D, et al. (2017) Generation of human induced pluripotent stem cell-derived bona fide neural stem cells for ex vivo gene therapy of metachromatic leukodystrophy. Stem Cells Transl Med 6: 352–368. doi: 10.5966/sctm.2015-0414
    [117] Messing A, LaPash Daniels CM, Hagemann TL (2010) Strategies for Treatment in Alexander Disease. Neurotherapeutics 7: 507–515. doi: 10.1016/j.nurt.2010.05.013
    [118] Prust M, Wang J, Morizono H, et al. (2011) GFAP mutations, age at onset, and clinical subtypes in Alexander disease. Neurology 77: 1287–1294. doi: 10.1212/WNL.0b013e3182309f72
    [119] Jones JR, Kong L, Hanna MG, et al. (2018) Mutations in GFAP Disrupt the Distribution and Function of Organelles in Human Astrocytes. Cell Rep 25: 947–958.e4. doi: 10.1016/j.celrep.2018.09.083
    [120] Kondo T, Funayama M, Miyake M, et al. (2016) Modeling Alexander disease with patient iPSCs reveals cellular and molecular pathology of astrocytes. Acta Neuropathol Commun 4: 69. doi: 10.1186/s40478-016-0337-0
    [121] Li L, Tian E, Chen X, et al. (2018) GFAP Mutations in Astrocytes Impair Oligodendrocyte Progenitor Proliferation and Myelination in an hiPSC Model of Alexander Disease. Cell Stem Cell 23: 239–251.e6. doi: 10.1016/j.stem.2018.07.009
    [122] Anheim M, Lagier-Tourenne C, Stevanin G, et al. (2009) SPG11 spastic paraplegia: A new cause of juvenile parkinsonism. J Neurol 256: 104–108. doi: 10.1007/s00415-009-0083-3
    [123] Örlén H, Melberg A, Raininko R, et al. (2009) SPG11 mutations cause Kjellin syndrome, a hereditary spastic paraplegia with thin corpus callosum and central retinal degeneration. Am J Med Genet B Neuropsychiatric Genet 150: 984–992.
    [124] Renvoisé B, Chang J, Singh R, et al. (2014) Lysosomal abnormalities in hereditary spastic paraplegia types SPG15 and SPG11. Ann Clin Trans Neurol 1: 379–389. doi: 10.1002/acn3.64
    [125] Murmu RP, Martin E, Rastetter A, et al. (2011) Cellular distribution and subcellular localization of spatacsin and spastizin, two proteins involved in hereditary spastic paraplegia. Mol Cell Neurosci 47: 191–202. doi: 10.1016/j.mcn.2011.04.004
    [126] Hirst J, Borner GH, Edgar J, et al. (2013) Interaction between AP-5 and the hereditary spastic paraplegia proteins SPG11 and SPG15. Mole Biol Cell 24: 2558–2569. doi: 10.1091/mbc.e13-03-0170
    [127] Pérez-Brangulí F, Mishra HK, Prots I, et al. (2014) Dysfunction of spatacsin leads to axonal pathology in SPG11-linked hereditary spastic paraplegia. Hum Mol Genet 23: 4859–4874. doi: 10.1093/hmg/ddu200
    [128] Mishra HK, Prots I, Havlicek S, et al. (2016) GSK3ß-dependent dysregulation of neurodevelopment in SPG11-patient induced pluripotent stem cell model. Ann Neurol 79: 826–840. doi: 10.1002/ana.24633
    [129] Varga RE, Khundadze M, Damme M, et al. (2015) In vivo evidence for lysosome depletion and impaired autophagic clearance in hereditary spastic paraplegia type SPG11. PLoS Genet 11: e1005454. doi: 10.1371/journal.pgen.1005454
    [130] LaMarca EA, Powell SK, Akbarian S, et al. (2018) Modeling neuropsychiatric and neurodegenerative diseases with induced pluripotent stem cells. Front Pediatr 6: 82. doi: 10.3389/fped.2018.00082
    [131] Tian F, Hao J, Hu L, et al. (2018) Modeling neurodegenerative diseases by human pluripotent stem cell-induced brain organoid. Transl Surg 3: 42. doi: 10.4103/ts.ts_4_18
    [132] Wang H (2018) Modeling neurological diseases with human brain organoids. Front Synaptic Neurosci 10: 15. doi: 10.3389/fnsyn.2018.00015
    [133] Gabriel E, Wason A, Ramani A, et al. (2016) CPAP promotes timely cilium disassembly to maintain neural progenitor pool. EMBO J 35: 803–819. doi: 10.15252/embj.201593679
    [134] Li Y, Muffat J, Omer A, et al. (2016) Induction of expansion and folding in human cerebral organoids. Cell Stem Cell 20: 385–396.e3.
    [135] Mariani J, Coppola G, Zhang P, et al. (2015) FOXG1-Dependent Dysregulation of GABA/Glutamate Neuron Differentiation in Autism Spectrum Disorders. Cell 162: 375–390. doi: 10.1016/j.cell.2015.06.034
    [136] Kim YG, Cha J, Chandrasegaran S (1996) Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. Proc Natl Acad Sci U S A 93: 1156–1160. doi: 10.1073/pnas.93.3.1156
    [137] Porteus MH, Baltimore D (2003) Chimeric nucleases stimulate gene targeting in human cells. Science 300: 763. doi: 10.1126/science.1078395
    [138] Wang Y, Zhang WY, Hu S, et al. (2012) Genome Editing of Human Embryonic Stem Cells and Induced Pluripotent Stem Cells With Zinc Finger Nucleases for Cellular Imaging. Circ Res 111: 1494–1503. doi: 10.1161/CIRCRESAHA.112.274969
    [139] Ramalingam S, London V, Kandavelou K, et al. (2013) Generation and genetic engineering of human induced pluripotent stem cells using designed zinc finger nucleases. Stem Cells Dev 22: 595–610. doi: 10.1089/scd.2012.0245
    [140] Wood AJ, Lo TW, Zeitler B, et al. (2011) Targeted Genome Editing Across Species Using ZFNs and TALENs. Science 333: 307–307. doi: 10.1126/science.1207773
    [141] Sanjana NE, Cong L, Zhou Y, et al. (2012) A transcription activator-like effector toolbox for genome engineering. Nat Protoc 7: 171–192. doi: 10.1038/nprot.2011.431
    [142] Cong L, Ran FA, Cox D, et al. (2013) Multiplex genome engineering using CRISPR/Cas systems. Science 339: 819–823. doi: 10.1126/science.1231143
    [143] Mali P, Yang L, Esvelt KM, et al. (2013) RNA-guided human genome engineering via Cas9. Science 339: 823–826. doi: 10.1126/science.1232033
    [144] Suzuki T, Asami M, Perry ACF (2015) Asymmetric parental genome engineering by Cas9 during mouse meiotic exit. Sci Rep 4: 7621. doi: 10.1038/srep07621
    [145] Smith C, Gore A, Yan W, et al. (2014) Whole-genome sequencing analysis reveals high specificity of CRISPR/Cas9 and TALEN-based genome editing in human iPSCs. Cell Stem Cell 15: 12–13. doi: 10.1016/j.stem.2014.06.011
    [146] Smith C, Abalde-Atristain L, He C, et al. (2015) Efficient and allele-specific genome editing of disease loci in human iPSCs. Mol Ther 23: 570–577. doi: 10.1038/mt.2014.226
    [147] He X, Li YX, Feng B (2018) New Turns for High Efficiency Knock-In of Large DNA in Human Pluripotent Stem Cells. Stem Cells Int 2018: 1–7.
    [148] Fu Y, Reyon D, Keith Joung J (2014) Targeted genome editing in human cells using CRISPR/Cas nucleases and truncated guide RNAs. Methods Enzymol 546: 21–45.
    [149] Tsai SQ, Wyvekens N, Khayter C, et al. (2014) Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing. Nat Biotechnol 32: 569–576. doi: 10.1038/nbt.2908
    [150] Raitano S, Ordovàs L, De Muynck L, et al. (2015) Restoration of progranulin expression rescues cortical neuron generation in an induced pluripotent stem cell model of frontotemporal dementia. Stem Cell Rep 4: 16–24. doi: 10.1016/j.stemcr.2014.12.001
    [151] Ebert AD, Yu J, Rose FF, et al. (2009) Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 457: 277–280. doi: 10.1038/nature07677
    [152] Simone C, Ramirez A, Bucchia M, et al. (2016) Is spinal muscular atrophy a disease of the motor neurons only: Pathogenesis and therapeutic implications? Cell Mol Life Sci 73: 1003–1020. doi: 10.1007/s00018-015-2106-9
    [153] Ramirez A, Crisafulli SG, Rizzuti M, et al. (2018) Investigation of New Morpholino Oligomers to Increase Survival Motor Neuron Protein Levels in Spinal Muscular Atrophy. Int J Mol Sci 19: E167. doi: 10.3390/ijms19010167
    [154] Klose RJ, Sarraf SA, Schmiedeberg L, et al. (2005) DNA Binding Selectivity of MeCP2 Due to a Requirement for A/T Sequences Adjacent to Methyl-CpG. Mol Cell 19: 667–678. doi: 10.1016/j.molcel.2005.07.021
    [155] Mellios N, Woodson J, Garcia RI, et al. (2014) β2-Adrenergic receptor agonist ameliorates phenotypes and corrects microRNA-mediated IGF1 deficits in a mouse model of Rett syndrome. Proc Natl Acad Sci U S A 111: 9947–9952. doi: 10.1073/pnas.1309426111
    [156] Chang Q, Khare G, Dani V, et al. (2006) The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression. Neuron 49: 341–348. doi: 10.1016/j.neuron.2005.12.027
    [157] Wang H, Chan SA, Ogier M, et al. (2006) Dysregulation of brain-derived neurotrophic factor expression and neurosecretory function in Mecp2 null mice. J Neurosci 26: 10911–10915. doi: 10.1523/JNEUROSCI.1810-06.2006
    [158] Li W, Pozzo-Miller L (2014) BDNF deregulation in Rett syndrome. Neuropharmacology 76: 737–746. doi: 10.1016/j.neuropharm.2013.03.024
    [159] Williams EC, Zhong X, Mohamed A, et al. (2014) Mutant astrocytes differentiated from Rett syndrome patients-specific iPSCs have adverse effects on wild-type neurons. Hum Mol Genet 23: 2968–2980. doi: 10.1093/hmg/ddu008
    [160] Zhu JM, Zhao YY, Chen SD, et al. (2011) Functional recovery after transplantation of neural stem cells modified by brain-derived neurotrophic factor in rats with cerebral ischaemia. J Int Med Res 39: 488–498. doi: 10.1177/147323001103900216
    [161] Behrstock S, Ebert AD, Klein S, et al. (2008) Lesion-induced increase in survival and migration of human neural progenitor cells releasing GDNF. Cell Transplant 17: 753–762. doi: 10.3727/096368908786516819
    [162] Hjelm BE, Grunseich C, Gowing G, et al. (2016) Mifepristone-inducible transgene expression in neural progenitor cells in vitro and in vivo. Gene Ther 23: 424–437. doi: 10.1038/gt.2016.13
  • This article has been cited by:

    1. Nejc Šarabon, Urška Čeklić, Comparison between gymnasts and non-gymnasts in isometric strength of the lower limbs, 2021, 2037-7460, 10.4081/ejtm.2021.9663
    2. M.F. Paulino, L.M. Roseiro, J.P. Dias, M.A. Neto, A.M. Amaro, Differences among plantar pressure of acrobatic gymnasts when they jump over two competition floors. Does the presence of mattresses affect the gymnasts’ performance?, 2020, 07651597, 10.1016/j.scispo.2020.05.006
    3. Catarina M. Amaro, Maria A. Castro, Luis Roseiro, Maria A. Neto, Ana M. Amaro, Plantar Pressure Evaluation during the Season in Five Basketball Movements, 2020, 10, 2076-3417, 8691, 10.3390/app10238691
    4. Bessem Mkaouer, Hounaida Akkari-Ghazouani, Samiha Amara, Raja Bouguezzi, Monèm Jemni, Helmi Chaabene, Kinetic and Kinematic Analysis of Landing during Standing Back Somersault Using Three Technical Arm Swings in Artistic Gymnastics, 2023, 8, 2411-5142, 10, 10.3390/jfmk8010010
    5. Marita L. HARRINGE, Stefan HÖÖG, Melanie SVENSSON, Gymnasts' experiences and perception of a cruciate ligament injury, 2022, 62, 00224707, 10.23736/S0022-4707.21.12358-8
    6. Víctor Hernández-Beltrán, Mário C. Espada, Jesús Muñoz-Jiménez, Kiko León, Cátia C. Ferreira, Jose A. Parraca, José M. Gamonales, Evolution of Documents Related to Biomechanics Research in Gymnastics, 2023, 3, 2673-7078, 477, 10.3390/biomechanics3040039
    7. Maria F. Paulino, Beatriz B. Gomes, Amílcar L. Ramalho, Ana M. Amaro, Measurement of the Impact Loads to Reduce Injuries in Acrobatic Gymnasts: Designing a Dedicated Platform, 2024, 14, 2076-3417, 3661, 10.3390/app14093661
    8. Kaysha Bates, Giorgio Zeppieri, Candace Young, Michelle Bruner, Michael Moser, Kevin W. Farmer, Federico Pozzi, Preseason lower extremity range of motion, flexibility, and strength in relation to in-season injuries in NCAA division I gymnasts, 2024, 52, 0091-3847, 200, 10.1080/00913847.2023.2215775
    9. Nili Steinberg, Liav Elbaz, Shelly Bar-Sela, Smadar Peleg, Alon Eliakim, Dan Nemet, Gali Dar, The relationship between physical features and patellofemoral-pain in young female gymnasts, 2025, 0091-3847, 10.1080/00913847.2025.2472741
  • Reader Comments
  • © 2019 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(5995) PDF downloads(1673) Cited by(1)

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog